SpyGlass Pharma — Third Quarter 2026 Earnings Summary

SpyGlass Pharma acquired Advanced Vision Science, Inc. for approximately $13 million to secure scalable manufacturing capacity for its lead product, the Bimatoprost Drug Pad-IOL System. The company announced four-year follow-up data from its first-in-human trial showing a 37% reduction in intraocular pressure and 86% of patients remaining off topical drops, while Phase 3 enrollment remains on track for completion in 2027. Additionally, the first implantations were completed for the Bimatoprost-Drug Ring System, a non-IOL-based delivery platform designed to provide up to seven years of treatment. For the third quarter ended September 30, 2026, the company reported a net loss of $24.3 million and held $215.8 million in cash and short-term investments.